Back to Peptides
VIP
Immune ModulationVasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that modulates immune response, dilates pulmonary vessels, and protects neural tissue. It is being studied for its potential role in treating pulmonary hypertension, COVID-19 respiratory failure, inflammatory and autoimmune disorders, and migraines.
Reconstitute
2 mL BAC + 5mg vial
25 mcg/unit
Daily Range
50–200 mcg Subcutaneous (SQ)
daily
Standard Dose
100 mcg
Cycle
4–8 weeks
then reassess
VIPVasoactive Intestinal Peptideimmune modulationpulmonary hypertensionneuroprotection
Dosing & Reconstitution Guide
In rodent studies, VIP has been administered at 5–50 μg/kg via intraperitoneal or intravenous injection. These doses are investigational and used only in controlled research settings.
Standard / Gradual Approach
5mg VialstandardPhaseDoseVolume
Week 1100mcg4 units
Week 2200mcg8 units
Week 3300mcg12 units
Week 4500mcg20 units
Protocol Summary
Subcutaneous (SQ): daily · Dose range 50–200 mcg with gradual titration
Intranasal: 1 spray per nostril, 3-4x daily · Dose range 50–200 mcg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Typically 100 mcg daily for 4–6 weeks for autoimmune or pulmonary inflammatory conditions. May repeat cycles as needed.
Intranasal
Useful for direct CNS and respiratory targeting; used daily or in cycles for neuroinflammation and MCAS protocols.
🧪 Quick Start
Vial Size
5 mg
BAC Water
2 mL
Concentration
2500 mcg/unit
Potential Benefits & Use Cases
Vasoactive Intestinal Peptide (VIP) is a research-use-only compound. It is not approved for human or veterinary use. All content is for educational and scientific reference only
Studied for reducing pro-inflammatory cytokines (e.g., IL-6, TNF-α) in immune cells
Explored in rodent models for protection against autoimmune inflammation
Investigated for lung and respiratory support in asthma and pulmonary hypertension models
May regulate circadian rhythm and brain-gut signaling in preclinical research
Interest in potential synergy with peptides like PACAP in neuroimmune regulation
Clinical data Strong preclinical Limited data
Mechanism of Action
→Binds to VPAC1 and VPAC2 receptors on immune, pulmonary, and neural tissues
→Suppresses pro-inflammatory cytokines (e.g., TNF-α, IL-6)
→Enhances T-regulatory cell function and dampens Th1/Th17 responses
→Acts as a neuropeptide with protective effects in CNS
Stacking Synergies
+
Thymosin Alpha-1
Enhanced immune regulation and viral defense
+
KPV
Synergistic anti-inflammatory effects in gut and systemic tissue
+
SS-31
Complements mitochondrial peptides like SS-31 for neuroimmune support
Lifestyle & Optimization
diet
Anti-inflammatory diet (Mediterranean style).
sleep
Sleep 7–9 hours nightly for immune recovery. Reduce stress through meditation.
timing
Intranasal or SubQ as prescribed. Consistent schedule.
exercise
Exercise moderately 3–4 times weekly.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Side Effects & Safety
Common Side Effects
• Nasal irritation with intranasal administration
• Mild flushing or hypotension
• Headache
Contraindications & Warnings
• May induce migraine in susceptible individuals
• Use cautiously in patients with asthma or vascular instability
Long-Term Safety Data
• Safety under long-term use still under evaluation; neuroprotective potential is under investigation
🧮 Dose Calculator
Concentration
25.0
mcg/unit
Draw Volume
20
units (0.200 mL)
For a 500 mcg dose, draw 20 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
Moderate bioavailability; slow systemic uptake and short half-life
Oral Administration
Poor; rapidly degraded by enzymes
Intranasal
Good for CNS and respiratory effects; bypasses GI degradation
Half-Life
5–10 minutes
Degradation
Degraded by plasma and tissue peptidases
Tissue Specificity
Targets lungs, immune cells, CNS, and vasculature
⚗️
Peptide Details
Molecular Weight
3327.9
Formula
C147H237N43O42S
Sequence
HSDAVFTDNYTRLRKQMAVKKYLNSILN
⚖️
Legal Status & Regulatory
RegionStatus
EUNot Approved
FDANot Approved
CanadaNot Approved
AustraliaNot Approved
Storage Instructions
Lyophilized (Powder)
Store lyophilized powder at 2-8°C
Reconstituted (Mixed)
After reconstitution, maintain at 2-8°C and use within 14-28 days. For intranasal use, transfer to spray bottle immediately.